Clyde Yancy, MD, FAHA, past president of the American Heart Association comments on the results of the SECURE trial, which found that treatment with a polypill containing aspirin, an ACE inhibitor, and atorvastatin and available in multiple dosing options significantly reduced the risk of recurrent major adverse cardiovascular events in elderly patients within six months of a myocardial infarction compared to standard care.
Related posts:
